Clinical trials: Progression-free Survival, open to volunteers
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Metastatic Colorectal Cancer
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic…
- Trial name
- CARE (NCT06425133)
- Testing
- Blood sample, Quality of life questionnaires, Biopsy
- Where
- 13 sites in France
- Volunteers
- 174 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Urothelial Carcinoma
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract…
- Trial name
- NCT06120374
- Testing
- Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 178 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Working Out M0 Bipolar Androgen Therapy
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).
- Trial name
- WOMBAT (NCT06594926)
- Testing
- Testosterone Enanthate
- Where
- 12 sites in Australia
- Volunteers
- 69 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Prostate Cancer, Prostate Adenocarcinoma
High-Risk prostatE Cancer radiatiOn Versus surgERy
Prospective cohort study comparing robot-assisted radical prostatectomy and external beam radiotherapy +/- androgen deprivation therapy for high-risk non-metastatic prostate cancer in terms of health-related quality of life…
- Trial name
- RECOVER (NCT05931419)
- Where
- 28 sites in Netherlands
- Volunteers
- 837 people
- Sponsor
- Comprehensive Cancer Centre The Netherlands
High-grade Glioma, Medulloblastoma
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade…
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- AflacBT2303 (NCT06624371)
- Testing
- Atovaquone, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Diffuse Large B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
- Trial name
- NCT05257018
- Testing
- R-CDOP+intrathecal MTX
- Where
- 2 sites in China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Glioblastoma
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is associated with poor prognosis despite standard treatment with maximal safe resection followed by radiotherapy plus temozolomide (the Stupp…
- Trial name
- ELITE (NCT07758062)
- Testing
- Levetiracetam Extended-Release Granules, Temozolomide (TMZ), Radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Tianjin Medical University General Hospital
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer Patients
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the…
- Trial name
- NCT06647680
- Testing
- Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC)
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional…
- Conditions
- Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS)
- Trial name
- NCT07322263
- Testing
- Intravesical Gemcitabine and Docetaxel
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Michael A. O'Donnell
Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
Patients with metastatic non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression below 50% are commonly treated with different chemo-immunotherapy regimens in routine clinical practice.
- Trial name
- ALCG-01 (NCT07394062)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab (1mg/kg)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Gazi University
Endometrial Neoplasms, Neoplasm Recurrence, Local
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial…
- Conditions
- Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06532539
- Testing
- Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Epithelial Ovarian Cancer, Ovarian Neoplasms
Centralization and Oncologic Outcomes in Ovarian Cancer
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Neoplasms, Advanced Ovarian Cancer
- Trial name
- COOC - REMO (NCT07075939)
- Testing
- No Intervention: Observational Cohort
- Where
- 7 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Malignant Phyllodes Tumor of the Breast
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
Malignant phyllodes tumor of the breast is a rare fibroepithelial tumor. Patients with metastatic or unresectable disease have limited systemic treatment options, and there remains a need for biomarkers that can dynamically…
- Trial name
- NCT07903181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University